ClinicalTrials.gg
CompletedNCT07333638Updated Jan 12, 2026

Phase II Clinical Study on the Efficacy and Safety of Naltrexone Implant in Patients With Alcohol Use Disorder

A Phase 2 interventional study of low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling) and high-dose group (naltrexone implant 1.5 g + general supportive psychological counseling) in AUD, sponsored by Shenzhen Sciencare Medical Industries Co., Ltd.. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-12.

Sponsored by Shenzhen Sciencare Medical Industries Co., Ltd. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 8 months after the study started (first participant enrolled Apr 2023, registered Dec 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
210
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial. The study plans to enroll 210 adult patients with alcohol use disorder. After signing the informed consent form and undergoing screening based on inclusion/exclusion criteria, eligible participants will be randomly assigned to the low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling), high-dose group (naltrexone implant 1.5 g + general supportive psychological counseling), and control group (placebo + general supportive psychological counseling) in a 1:1:1 ratio. On Day 0, participants will receive a single subcutaneous abdominal incision implantation with either 0.9 g or 1.5 g of naltrexone implant or placebo. Efficacy assessment will follow up to 24 weeks after randomization/dosing, while safety assessment will follow up to 48 weeks. There will be a total of 13 follow-up visits. Except for Day 3 (Visit 3) and Week 36 (Visit 12), which are telephone follow-ups, all other visits will be outpatient follow-ups. The first 24 weeks of the study will be double-blind. After completing the Week 24 follow-up, all participants will undergo efficacy assessment. Then they will enter the open-label observation period, followed up until Week 48.

02

Conditions studied

  • AUD

Keywords

  • naltrexone implant
03

In context

Lead sponsor

Shenzhen Sciencare Medical Industries Co., Ltd. is the lead sponsor of 4 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily participate in the clinical study; fully understand and are informed about the study and sign the form; willing and able to comply with and complete all trial procedures; \|
  2. Age ≥18 years at the time of signing the informed consent form; \|
  3. Diagnosis of moderate or severe Alcohol Use Disorder based on the , Fifth Edition (DSM-5) (meeting four or more diagnostic criteria, see Appendix 1 for details); \|
  4. Completed detoxification treatment and had no significant alcohol withdrawal symptoms for at least one week (≥7 days) prior to randomization/administration [Clinical Institute Withdrawal Assessment for Alcohol-Revised (CIWA-Ar) score \<7 points (see Appendix 2 for specific assessment method)]; \|
  5. Able to provide Timeline Followback (TLFB) alcohol use information for the 2 weeks during detoxification and/or prior to screening; \|
  6. Had at least two heavy drinking days per week during the 4 weeks of detoxification and/or prior to screening; \|
  7. Qualified subjects of (male and female) must agree to use effective methods (hormonal or barrier method or abstinence) with their partner during the trial period.

Exclusion criteria

Exclusion Criteria:

  1. The investigator judges that participation in this study is not in the best interest of the subject, or any other condition that would make it unsafe for the subject to participate in the study; \|
  2. Pregnancy, positive pregnancy test for women of , or lactating women, including women of childbearing potential planning to become pregnant during the study period. Note: Women of childbearing potential here refer to women capable of becoming pregnant. Must meet the following criteria, regardless of sexual orientation or tubal ligation: 1) No hysterectomy or bilateral oophorectomy; or 2) Have not been naturally for more than 12 consecutive months (i.e., have had menses at any time in the preceding 12 consecutive months); \|
  3. Significant abnormal liver function (e.g., or ALT >2 times the ) or liver failure [including but not limited to: ascites, prolonged , International Normalized Ratio (INR) ≥1.7, esophageal variceal disease] or hepatobiliary ultrasound shows results that significantly impact the judgment of the study drug's efficacy and safety; \|
  4. Suffering from clinically uncontrolled active infectious diseases, such as active [Hepatitis B surface antigen (HBsAg) positive and Hepatitis B virus (HBV) DNA copy number >1000 IU/ml], active [Hepatitis C virus antibody positive and Hepatitis C virus (HCV)-RNA positive], etc.; \|
  5. History of congenital bleeding disorders (e.g., hemophilia) or any active bleeding, or dysfunction, or prothrombin time (PT) exceeding the upper normal limit by more than 3 seconds, or platelet count \<50×10⁹/L; \|
  6. Previous history of severe pancreatitis or severe delirium tremens;
  7. In the investigator's judgment, the subject has any severe/uncontrolled systemic disease (e.g., respiratory, circulatory, digestive, nervous, hematological, urogenital, endocrine systems) or mental illness (e.g., major depressive disorder, schizophrenia, bipolar disorder, etc.) or other major diseases that the investigator believes would prevent providing , make participation in the study unsafe, complicate the interpretation of study outcome data, or otherwise affect the achievement of study objectives;
  8. Likely to require hospitalization or surgery during the study period, including planned elective surgery or hospitalization that cannot be postponed;
  9. Diagnosed with substance use disorder (other than alcohol) according to criteria within the current (within one year prior to randomization/administration) period, such as: benzodiazepines, amphetamines, opioids, or cocaine, etc.; \|
  10. Used medications for relapse prevention (e.g., naltrexone, etc.) or received systematic psychological support therapy within 30 days prior to randomization/administration;
  11. Currently receiving treatment for opioid, amphetamine, alcohol, or other substance use disorders, or received opioids within 7 days prior to randomization/administration, likely to require opioid treatment during the study period, or positive urine test for opioids, marijuana, amphetamines, etc., or positive naloxone challenge test on the day of randomization/administration; 12. Allergy to the drug or its (polylactic acid, magnesium stearate), or local anesthetics; \|

13. Currently participating in any investigational drug or device study, or used any investigational drug or device within 30 days prior to randomization/administration; 14. Skin infection at the implantation site or systemic skin disease judged to potentially affect the efficacy and safety evaluation of the investigational drug; \| 15. Clinical or laboratory evidence of (HIV) or syphilis carrier/infection. \|

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
210 participants (actual)

Study arms

  • Experimental
    low-dose group (naltrexone implant 0.9 g )

    Drug: low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling)

  • Experimental
    high-dose group (naltrexone implant 1.5 g )

    Drug: high-dose group (naltrexone implant 1.5 g + general supportive psychological counseling)

  • Placebo comparator
    control group (placebo )

    Other: control group (placebo + general supportive psychological counseling)

Interventions

  • Druglow-dose group (naltrexone implant 0.9 g + general supportive psychological counseling)

    Drug page: Naltrexone

    low-dose group (naltrexone implant 0.9 g + general supportive psychological counseling)

  • Drughigh-dose group (naltrexone implant 1.5 g + general supportive psychological counseling)

    Drug page: Naltrexone

    high-dose group (naltrexone implant 1.5 g + general supportive psychological counseling)

  • Othercontrol group (placebo + general supportive psychological counseling)

    control group (placebo + general supportive psychological counseling)

06

What researchers measure

Primary outcomes

  1. Proportion of heavy drinking days during the 24-week observation period post-randomization/treatment

    The "Heavy Drinking Days" are divided by the "Days at Risk of Heavy Drinking", with both calculations ending at the cessation of efficacy observation. "Days at Risk of Heavy Drinking" refers to the number of days participants receive efficacy observation during the study. Drinking rates are assessed based on daily alcohol consumption records completed by participants and their families, using the Timeline Follow-Back (TLFB) method. Heavy drinking is defined as "≥5 standard drinks per day for males and ≥4 standard drinks per day for females (In this trial, 1 standard drink = 10 g of pure alcohol).

    Time frame: 24-week

Secondary outcomes

  1. Change in number of heavy drinking days per month relative to baseline

    Specifically, the comparison of total monthly heavy drinking days from randomization/drug administration to the end of follow-up/trial completion with baseline monthly heavy drinking days \[calculate monthly corresponding data for weeks 1-24 after randomization/drug administration\]; alcohol consumption rate is assessed using the Timeline Follow-Back (TLFB) method based on daily alcohol consumption records completed by subjects and their families . Heavy drinking is defined as "≥5 standard drinks per day for males and ≥4 standard drinks per day for females (in this trial, 1 standard drink = 10 g of pure alcohol).

    Time frame: 24-week

  2. Alcohol-free days percentage

    The "number of alcohol-free days" is divided by the "number of days at risk of alcohol consumption", with both calculations ending at the cessation of efficacy observation. The "number of days at risk of alcohol consumption" is defined as the number of days during which participants receive efficacy observation in the study. According to the Time-Line Follow-Back (TLFB) method, this is calculated based on alcohol consumption records; alcohol consumption is defined as any recorded alcohol consumption behavior, regardless of the quantity or frequency of consumption.

    Time frame: 24-week

  3. Maximum Consecutive Days of Abstinence

    The longest period of continuous alcohol abstinence from randomization/dosing to loss of follow-up/study completion; calculated based on daily alcohol consumption records completed by subjects and their families using the Timeline Follow-Back (TLFB) method.

    Time frame: 24-week

  4. Daily and Weekly Alcohol Consumption (Daily Drinking Amount and Weekly Total Drinking Amount)

    Daily drinking amount and weekly total drinking amount for the corresponding period; calculated based on weekly data from 1 to 24 weeks after randomization/dosing; calculated using the TLFB method based on daily drinking records completed by subjects and their families.

    Time frame: 24-week

  5. Alcohol Breath Concentration

    Random/Post-dosing at 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and 24 weeks; measured by digital alcohol breath tester.

    Time frame: 24-week

  6. Alcohol Craving Assessment

    Randomized/Post-treatment scores at 1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 16 weeks, 20 weeks, and 24 weeks; assessed using Visual Analogue Scale (VAS). VAS assessment: One end of the horizontal line is "0", indicating no craving at all; the other end is "10", indicating extreme craving; the middle section represents varying degrees of craving. Participants are asked to select a number from 0-10 that represents their level of craving based on self-perception. The higher the number, the greater the degree of craving.

    Time frame: 24-week

  7. Alcohol Consequences Score

    Randomized/Post-treatment at weeks 4, 8, 12, 16, 20, and 24; assessed using the Alcohol Consequences Checklist

    Time frame: 24-week

  8. Individual and Social Functioning Status

    Assessment of individual and social functioning status at random/4, 8, 12, 16, 20, and 24 weeks post-treatment; Evaluated based on the Personal and Social Performance (PSP) scale: A total score of 71-100 indicates no difficulty or only mild difficulty in social functioning and interpersonal relationships A total score of 31-70 indicates varying degrees of impairment in social functioning and interpersonal relationships A total score below 30 indicates poor functioning, requiring active support or close supervision

    Time frame: 24-week

  9. Follow-up duration (from randomization/dosing to last follow-up)

    defined as the time from randomization/dosing to the last follow-up visit.

    Time frame: 24-week

  10. The proportion of subjects with poor treatment response

    defined as the proportion of subjects who were hospitalized for alcohol withdrawal, picked up medication, or lost to follow-up due to poor treatment response;"lost to follow-up due to poor treatment response" is defined as having ≥2 heavy drinking days per week in the 4 weeks prior to loss to follow-up.

    Time frame: 24-week

  11. Safety assessment indicators

    including adverse events (AE) and serious adverse events (SAE) (including local AE and SAE at the implant site), abnormal occurrences of vital signs, physical examination, 12-lead or more ECG, and laboratory safety data (blood routine, urine routine, clinical biochemistry, and coagulation routine) before and after treatment.

    Time frame: 48-week

07

Study locations

1 site
  • The Second Xiangya Hospital of Central South University Address: No. 139, Renmin Road Central, Changsha City
    Changsha, Hunan 410011, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Sep 2024, 17 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 30, 2025
First posted
Jan 12, 2026
StartActual
Apr 3, 2023
Primary completionActual
Sep 27, 2024
CompletionActual
Oct 10, 2024
Last update
Jan 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07333638
Lead sponsor
Shenzhen Sciencare Medical Industries Co., Ltd.
Responsible party
Sponsor
First posted
Jan 12, 2026
Start date
Apr 3, 2023
Primary completion
Sep 27, 2024
Completion
Oct 10, 2024
Last update
Jan 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Naltrexone

Start the discussion